220 related articles for article (PubMed ID: 24074783)
1. Management of breast cancer in very young women.
Freedman RA; Partridge AH
Breast; 2013 Aug; 22 Suppl 2():S176-9. PubMed ID: 24074783
[TBL] [Abstract][Full Text] [Related]
2. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
3. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
[TBL] [Abstract][Full Text] [Related]
4. Management of breast cancer in very young women.
Rosenberg SM; Partridge AH
Breast; 2015 Nov; 24 Suppl 2():S154-8. PubMed ID: 26255745
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapies for very young women with early stage breast cancer.
Freedman RA; Partridge AH
Breast; 2011 Oct; 20 Suppl 3():S146-9. PubMed ID: 22015283
[TBL] [Abstract][Full Text] [Related]
6. Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Dickler M
Nat Clin Pract Oncol; 2005 Oct; 2(10):498-9. PubMed ID: 16205767
[No Abstract] [Full Text] [Related]
7. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant hormonal therapy in perimenopausal patients.
Pinto Marín A; Ballesteros García AI; Izarzugaza Perón Y; Mansó Sánchez L; López-Tarruella Cobo S; Zamora Auñón P
Adv Ther; 2011 Sep; 28 Suppl 6():39-49. PubMed ID: 21922394
[TBL] [Abstract][Full Text] [Related]
9. Who should not undergo breast conservation?
Nijenhuis MV; Rutgers EJ
Breast; 2013 Aug; 22 Suppl 2():S110-4. PubMed ID: 24074770
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Ingle JN
Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
[TBL] [Abstract][Full Text] [Related]
11. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
[TBL] [Abstract][Full Text] [Related]
12. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
[TBL] [Abstract][Full Text] [Related]
13. Optimal adjuvant therapy for very young breast cancer patients.
Francis PA
Breast; 2011 Aug; 20(4):297-302. PubMed ID: 21605976
[TBL] [Abstract][Full Text] [Related]
14. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant treatment for young women with early breast cancer.
Balduzzi A; Cardillo A; D'Alessandro C; Colleoni M
Minerva Ginecol; 2007 Oct; 59(5):513-27. PubMed ID: 17912178
[TBL] [Abstract][Full Text] [Related]
17. Update on adjuvant hormonal treatment of early breast cancer.
Lao Romera J; Puertolas Hernández TJ; Peláez Fernández I; Sampedro Gimeno T; Fernández Martínez R; Fernández Pérez I; Iranzo González Cruz V; Illarramendi Mañas JJ; Garcerá Juan S; Ciruelos Gil EM
Adv Ther; 2011 Sep; 28 Suppl 6():1-18. PubMed ID: 21922392
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer.
Fyles AW; McCready DR; Manchul LA; Trudeau ME; Merante P; Pintilie M; Weir LM; Olivotto IA
N Engl J Med; 2004 Sep; 351(10):963-70. PubMed ID: 15342804
[TBL] [Abstract][Full Text] [Related]
19. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
Hughes KS; Schnaper LA; Berry D; Cirrincione C; McCormick B; Shank B; Wheeler J; Champion LA; Smith TJ; Smith BL; Shapiro C; Muss HB; Winer E; Hudis C; Wood W; Sugarbaker D; Henderson IC; Norton L; ; ;
N Engl J Med; 2004 Sep; 351(10):971-7. PubMed ID: 15342805
[TBL] [Abstract][Full Text] [Related]
20. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Benson JR
J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
[No Abstract] [Full Text] [Related]
[Next] [New Search]